Roche/Ipsen's Suspended Taspoglutide Could Become Another Diabetes Casualty

Roche confirms suspension of dosing in Phase III taspoglutide program after reporting safety problems in June. But Roche's pain could be a gain for the competing GLP-1 Bydureon from Lilly/Amylin/Alkermes.